591-55-9

Usage

Purification Methods

It is purified by conversion to the MgCl2 complex in a small volume of H2O. The complex (~ 5g) is dissolved in the minimum volume of hot H2O, passed through a column of activated Al2O3 (200g), and the column is washed with EtOH. Evaporation of the EtOH gives a colourless residue of the aminopyrimidine which is recrystallised from *C6H6 (toluene could also be used) which forms needles at first, then prisms. It melts with sublimation. Acetylation yields 5-acetamidopyrimidine which crystallises from *C6H6, m 148-149o. [Whittaker J Chem Soc 1565 1951.]

InChI:InChI=1/C4H5N3/c5-4-1-6-3-7-2-4/h1-3H,5H2

Upstream product

• 5177-27-5 5-amino-2,4-dichloropyrimidine 
• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 14001-70-8 2-(methylthio)-5-nitropyrimidine 
• 53180-76-0 (3,5-dichloropyridazin-4-yl)amine 
• 4316-93-2 4,6-dichloro-5-nitropyrimidine 
• 4595-59-9 5-bromopyrimidine 
• 79691-74-0 5-(α-hydroxyethyl)pyrimidine 
• 88317-72-0 4,6-bismethylthio-5-nitropyrimidine 

Downstream Products

• 45810-14-8 5-Acetamido-pyrimidin 
• 103854-65-5 N-pyrimidin-5-yl-benzamide 
• 75378-62-0 1-phenyl-2-methyl-4-formylimidazole 
• 75378-58-4 N-(5-pyrimidinyl)-N'-phenylacetamidine 
• 81541-87-9 4-p-Tolyl-6-p-tolylazo-pyrimidin-5-ylamine 
• 81541-88-0 4-p-Tolyl-6-p-tolylazo-pyrimidin-5-ol 
• 75378-61-9 1,2-diphenyl-1H-imidazole-4-carbaldehyde 
• 75378-57-3 N-(5-pyrimidinyl)-N'-phenylbenzamidine 
• 81541-85-7 4-Phenyl-6-phenylazo-pyrimidin-5-ylamine 
• 81541-86-8 4-Phenyl-6-phenylazo-pyrimidin-5-ol 
• 81541-89-1 C₁₀H₈BrN₅ 
• 81557-49-5 4-(4-Bromo-phenyl)-6-(4-bromo-phenylazo)-pyrimidin-5-ylamine 
• 81541-90-4 4-(4-Bromo-phenyl)-6-(4-bromo-phenylazo)-pyrimidin-5-ol 
• 75378-60-8 N-phenyl-N'-(5-pyrimidinyl)formamidine 

Relevant academic research and scientific papers

Aromatic amine compound synthesis method

The invention discloses an aromatic amine compound synthesis method which is characterized in that the method is implemented according to any of two methods. The first method includes the steps: mixing an alkyl aromatic compound with a general formula (I) and a nitrogen-containing compound with a general formula (II); performing reaction on mixture under an oxidizing agent and an organic solvent to obtain an aromatic amine compound with a general formula (III). The second method includes the steps: mixing an aromatic alcohol derivative with a general formula (I') and the nitrogen-containing compound with the general formula (II); performing reaction on mixture under an acid additive and an organic solvent to prepare the aromatic amine compound with the general formula (III). According to the method, a lot of alkyl aromatic compounds or aromatic alcohol derivatives firstly serve as raw materials, and the raw materials are reacted to generate the aromatic amine compound without the action of metal catalysis. Compared with a traditional synthesis method, the synthesis method has the advantages that the method is high in yield and simple in condition, waste discharging amount is less,metal participation is omitted, a reaction device is simple, industrial production is easily achieved and the like. The method has a wide application prospect.

Selective Cross-Coupling of (Hetero)aryl Halides with Ammonia to Produce Primary Arylamines using Pd-NHC Complexes

Herein we report the first example of (hetero)arylation of ammonia using a monoligated palladium-NHC complex. The new, rationally designed, precatalyst (DiMeIHeptCl)Pd(allyl)Cl featuring highly branched alkyl chains has been shown to be effective in selective aminations across a range of challenging substrates, including nitrogen-containing heterocycles and those featuring base-sensitive functionality. The less bulky Pd-PEPPSI-IPentCl precatalyst performs well for ortho-substituted aryl halides, giving monoarylated products in high yield with good selectivity.

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity

Preparation of highly reactive pyridine- and pyrimidine-containing diarylamine antioxidants

We recently reported a preliminary account of our efforts to develop novel diarylamine radical-trapping antioxidants (Hanthorn, J. J. et al. J. Am. Chem. Soc. 2012, 134, 8306-8309) wherein we demonstrated that the incorporation of ring nitrogens into diphenylamines affords compounds which display a compromise between H-atom transfer reactivity to peroxyl radicals and stability to one-electron oxidation. Herein we provide the details of the synthetic efforts associated with that report, which have been substantially expanded to produce a library of substituted heterocyclic diarylamines that we have used to provide further insight into the structure-reactivity relationships of these compounds as antioxidants (see the accompanying paper, DOI: 10.1021/jo301012x). The diarylamines were prepared in short, modular sequences from 2-aminopyridine and 2-aminopyrimidine wherein aminations of intermediate pyri(mi)dyl bromides and then Pd-catalyzed cross-coupling reactions of the amines and precursor bromides were the key steps to yield the diarylamines. The cross-coupling reactions were found to proceed best with Pd(η3-1-PhC3H 4)(η5-C5H5) as precatalyst, which gave higher yields than the conventional Pd source, Pd2(dba) 3.

Synthesis of [14C]-, [13C4]-, and [ 13C4, 15N2]-5-amino-4-iodopyrimidine

5-Amino-4-iodopyrimidine labeled with either carbon-14 or with the stable isotopes carbon-13 and nitrogen-15 was prepared starting from commercially available labeled diethylmalonate and formamide. This compound is a useful intermediate for carbon-nitrogen and carbon-carbon bond formations. Copyright

AMIDE COMPOUND

There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO

Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Aromatic nitrogen-containing 6-membered cyclic compounds

An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R3 (R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R4 (R4 is a substituted or unsubstituted cycloalkyl group); R2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

Synthesis of 5-phenyl-10-methyl-7H-pyrimido[4,5-f][1,2,4]triazolo[4,3-a][1,4]diazepine and its evaluation as an anticonvulsant agent

The homolytic benzoylation (benzoyl radical) of 5-tert-butylcarbonylaminopyrimidine (6, 1 equiv.) in the presence of benzaldehyde (3 equiv.), water, sulfuric acid, and acetic acid, upon treatment with FeSO4·7H2O (3 equiv.) and 70% t-